Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors: Consensus Round Table, Scottsdale (Arizona), March 22, 1987 by T.M. O'DorisioSandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors: Consensus Round Table, Scottsdale (Arizona), March 22, 1987 by T.M. O'Dorisio

Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors: Consensus Round Table…

EditorT.M. O'Dorisio

Paperback | October 12, 2011

Pricing and Purchase Info

$159.25 online 
$167.95 list price save 5%
Earn 796 plum® points
Quantity:

In stock online

Ships free on orders over $25

Not available in stores

about

The secretion of bioactive products by tumors of the gastroenteropancreatic system results in the development of watery diarrhea that can lead to death in a very short period if not brought under control. Even if the consequences are less dramatic, the patients' ability to lead a normal daily life is seriously impaired, and they may become severely depressed. SandostatinR alleviates the condition by inhibiting peptide release, and its long duration of action makes it an effective and rational adjunct to therapy at all stages. Last year a consensus Round Table Meeting was held in Scottsdale, Arizona, to discuss the optimal use of SandostatinR in this indication. These guidelines offer the results of clinical research and the dosage recommendations arising from them, together with a critical summary of the points of view presented.
Title:Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors: Consensus Round Table…Format:PaperbackDimensions:154 pages, 9.61 × 6.69 × 0.03 inPublished:October 12, 2011Publisher:Springer Berlin HeidelbergLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:3642647944

ISBN - 13:9783642647949

Look for similar items by category:

Reviews

Table of Contents

Contents: Prologue.- Chemical Structure - Pharmacological Profile of SandostatinR.- Carcinoid Tumours and the Carcinoid Syndrome.- Tumors of the Gastroenteropancreatic Axis.- The Use of SandostatinR in Insulinomas. The Relation Between In Vivo Responses, the Presence of Somatostatin Receptors and the Development of Tachyphylaxis.- SandostatinR: Assay and Efficacy in VIPoma and Insulinoma.- SandostatinR in Digestive Endocrine Tumors.- VIPoma, Gastrinoma and Glucagonoma.- Rebound Effect and Escape of Diarrhea Inhibition Using SandostatinR in VIPoma Patients.- Long-Term Treatment of VIPoma and Glucagonoma with SandostatinR.- Therapy of the Malignant Carcinoid Syndrome and Metastatic Islet Cell Carcinoma.- SandostatinR in the Treatment of Advanced Malignancies.- Treatment of Malignant Neuroendocrine Gut and Pancreatic Tumors with SandostatinR.- SandostatinR and Gastroenteropancreatic Endocrine Tumors - Therapeutic Characteristics.- Consensus.- Future Directions.- Bibliography.